 Omeros Corporation Nasdaq: OMER today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 MASP-2, in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome ARDS, a severe and life-threatening symptom of COVID-19. All patients initially required mechanical ventilation, and all recovered and survived with narsoplimab treatment. A manuscript detailing the results of the study has been accepted for publication in the peer-reviewed journal Immunobiology. A pre-publication copy of the manuscript can be accessed at 